Filing Flows › 8-K events › Theriva Biologics
Theriva Biologics: completion of an acquisition or disposition of assets
Form 8-K filed Nov 2, 2026 · items 1.01, 2.01, 7.01
Completion of an acquisition or disposition of assetsTheriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
What the filing says
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. The Closing occurred on October 30, 2026.
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.01: +0.1% next session across 2,671. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.
Theriva Biologics at a glance
Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%. The chart follows the revenue to costs, profit and cash.
Theriva Biologics: every quarter, Q/Q and Y/Y, holders and guidance →
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.